On Thursday, RXi Pharmaceuticals Corp (NASDAQ:RXII)’s shares enhanced 3.97%, and closed at $0.733, hitting new 52-week low of $0.68, as RXi Pharmaceuticals Corporation (RXII), stated its financial results for the fourth quarter and year ended December 31, 2014, and offered a business update.
The past year has seen a steady growth and evolution for RXi Pharmaceuticals,” said Dr. Geert Cauwenbergh, President and CEO of the Corporation. He added that, “In 2014 we harvested the first results from our first Phase 2a study with RXI-109 that demonstrate that our drug is active in the target population. These results offered us with guidance on treatment regimen and duration for RXI-109 in patients with hypertrophic scars. Add to that our progress in ophthalmology towards a clinical trial for retinal scarring, in addition to the attainment of Samcyprone™, and we feel that we are well positioned to extend our growth curve into the current year; all while focusing on containing cash burn in line with expectations for a biotechnology stage corporation that is in mid-stage development with its first two products.”
RXi Pharmaceuticals Corporation, a biotechnology corporation, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The corporation develops therapies based on siRNA technology and immunotherapy agents.
QEP Resources Inc (NYSE:QEP), inclined 3.93%, and closed at $21.70, following the declaration by QEP Resources, Inc. (QEP) that it will host a teleconference and webcast to talk about its first quarter 2015 results starting at 9:00 a.m. EDT (7:00 a.m. MDT) on Thursday, April 30, 2015. QEP will issue a combined first quarter financial and operations news release Wednesday, April 29, 2015 after market close.
QEP Resources, Inc., through its auxiliaries, operates as an exploration and production corporation. The corporation attains, explores, develops, and produces natural gas, oil, and natural gas liquids (NGLs) primarily in the Pinedale Anticline in western Wyoming; the Williston Basin in North Dakota; the Uinta Basin in eastern Utah; the Permian Basin in western Texas; the Haynesville/Cotton Valley in northwestern Louisiana; and other proven properties in Wyoming, Utah, and Colorado.
At the end of Thursday’s trade, Gol Linhas Aereas Inteligentes SA (ADR) (NYSE:GOL), surged 3.90%, and closed at $2.40, as the largest low-cost and best-fare airline in Latin America, declared its 4Q14 Results.
Highlights:
Operating revenue (EBIT) of R$505 million in 2014, with an operating margin of 5.0%, up 89.8% contrast to R$266 million recorded in 2013. In 4Q14, EBIT came to R$170.7 million, a 4.8% improvement over 4Q13, with a margin of 6.3%, up by 0.3 percentage point.
Net proceed reached R$10 billion in the year, 12.4% more than in 2013, being R$9.0 billion in passenger proceed and R$1 billion in ancillary proceeds, increasing its share of total proceed from 9.3%, in 2013, to 10.1%. International proceed amounted to R$1.2 billion, equivalent to 12% of the total. In 4Q14, net proceed totaled R$2.7 billion, in line with 4Q13.
Gol Linhas Aéreas Inteligentes S.A. provides regular and non-regular air transportation services for passengers, cargoes, and mailbags in Brazil and internationally. It operates in two segments, Flight Transportation and Smiles Loyalty Program.
CNO Financial Group Inc (NYSE:CNO), gained 3.85%, and closed at $17.79, as CNO Financial Group is going to replace Salix Pharmaceuticals (SLXP) in the S&P MidCap 400 after the close of trading on Monday, April 6. Valeant Pharmaceuticals (VRX) accomplished the attainment of Salix Pharmaceuticals earlier recently.
CNO Financial Group is a holding corporation that sells insurance throughout the US. Headquartered in Carmel, Indiana, the corporation will be added to the S&P MidCap 400 GICS (Global Industry Classification Standard) Life & Health Insurance Sub-Industry index.
CNO Financial Group, Inc., through its auxiliaries, develops, markets, and administers health insurance, annuity, individual life insurance, and other insurance products for senior and middle-revenue markets in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
